Recital 23, Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refus…

In forcesince 21 Oct 2009

Following an application from BIO SERAE submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of NeOpuntia® on blood lipid parameters associated with cardiovascular risks, especially HDL-cholesterol (Question No EFSA-Q-2008-214) [The EFSA Journal (2008) 788, 1-2.]. The claim proposed by the applicant was worded as follows: ‘NeOpuntia® helps to improve blood lipid parameters associated with cardiovascular risks, especially the HDL-cholesterol’.